分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

EP300/NCOA1 complex drives glioma angiogenesis via H3K27 acetylation–dependent activation of VEGFA

Shidi Yang, Xiaoyan Yao, Xiuwen Lin, Dengfeng Yang, Xiang Ying

Journal:EXPERIMENTAL CELL RESEARCH

IF:3.5

DOI:10.1016/j.yexcr.2026.115004

PMID:41921814

Published:2026-03-30

research field:肿瘤学分子生物学癌症生物学血管生成研究表观遗传学

Abstract

Angiogenesis is essential for glioma progression, yet the epigenetic mechanisms driving this process remain incompletely defined. In this study, we investigated the role of the histone acetyltransferase EP300 in regulating VEGFA expression and promoting endothelial activation. Using glioma cell lines with EP300 overexpression or knockdown, we found that EP300 markedly enhanced endothelial proliferation, invasion, and tube formation, while its silencing produced opposite effects. Mechanistic analyses revealed that EP300 increased H3K27 acetylation at the VEGFA promoter, thereby activating VEGFA transcription. Pharmacologic blockade of EP300 activity or VEGFA neutralization abolished these pro-angiogenic effects. Through integrative analysis of TCGA data and protein complex databases, NCOA1 was identified as a key EP300-associated cofactor. Co-immunoprecipitation and nuclear-cytoplasmic assays confirmed that EP300 forms a nuclear transcriptional co-activator complex with NCOA1, which stabilizes its nuclear localization and synergistically enhances VEGFA expression. Together, these findings identify EP300 as a central epigenetic regulator of glioma angiogenesis and highlight the EP300/NCOA1–VEGFA axis as a potential therapeutic target.

本文使用的Yeasen产品

购物车
客服
转染试用